The first large scale study in the U.S. on the mortality of patients with multiple sclerosis (MS) has been published and provides new information about the life expectancy of people with the disease. The study appears in the journal Multiple Sclerosis and Related Disorders.
Researchers from the Slone Epidemiology Center at Boston University took the first large scale study in the United States regarding mortality and a chronic disease of the central nervous system, multiple sclerosis (MS). At this time, there are roughly 250,000 to 350,000 patients living with MS in the United States. That’s approximately one in 1,000, according to background information from the study. As the degenerative phase affects the majority of patients, despite disease modifying-agents to reduce the activity of the health issue, many must face the possibility of a decreased life span due to the health problem.
The new guidelines for use of statins could result in millions more users (“Panel recommends far wider use of cholesterol drugs,” Page A1, Nov. 13). However, thanks to Dr. Paul Ridker, a cardiologist at Brigham and Women’s Hospital, and Nancy Cook, a biostatistician at Brigham, the public has learned that the risk calculator for cardiovascular disease suggested by the American Heart Association and American College of Cardiology overestimates risk (“Heart doctors at odds on risk formula,” Page A1, Nov. 19). This would result in millions being wrongly considered to meet the new guideline for statin use.